Does RAMUCIRUMAB Cause Malignant neoplasm progression? 743 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 743 reports of Malignant neoplasm progression have been filed in association with RAMUCIRUMAB (CYRAMZA). This represents 13.9% of all adverse event reports for RAMUCIRUMAB.
743
Reports of Malignant neoplasm progression with RAMUCIRUMAB
13.9%
of all RAMUCIRUMAB reports
343
Deaths
243
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RAMUCIRUMAB?
Of the 743 reports, 343 (46.2%) resulted in death, 243 (32.7%) required hospitalization, and 53 (7.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RAMUCIRUMAB. However, 743 reports have been filed with the FAERS database.
What Other Side Effects Does RAMUCIRUMAB Cause?
Death (492)
Interstitial lung disease (269)
Febrile neutropenia (229)
Neutropenia (229)
Decreased appetite (187)
Diarrhoea (186)
Hypertension (175)
Pyrexia (161)
Nausea (160)
Fatigue (159)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RAMUCIRUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
RAMUCIRUMAB vs RANEXA
RAMUCIRUMAB vs RANIBIZUMAB
RAMUCIRUMAB vs RANIMUSTINE
RAMUCIRUMAB vs RANITIDINE
RAMUCIRUMAB vs RANITIDINE\RANITIDINE